{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:42:04Z","timestamp":1794037324766,"version":"4.8.0"},"reference-count":187,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Treatment of blood malignancies and other cancer diseases has been mostly unfeasible, so far. Therefore, novel treatment regimens should be developed and the currently used ones should be further elaborated. A stable component in various cancer treatment regimens consists of vincristine, an antimitotic compound of natural origin. Despite its strong anticancer activity, mostly, it cannot be administered as monotherapy due to its unspecific action and severe side effects. However, vincristine is suitable for combination therapy. Multidrug treatment regimens including vincristine are standardly applied in the therapy of non-Hodgkin lymphoma and other malignancies, in which it is combined with drugs of different mechanisms of action, mainly with DNA-interacting compounds (for example cyclophosphamide), or drugs interfering with DNA synthesis (for example methotrexate). Besides, co-administration of vincristine with monoclonal antibodies has also emerged, the typical example of which is the anti-CD20 antibody rituximab. Although in some combination anticancer therapies, vincristine has been replaced with other drugs exhibiting lesser side effects, though, in most cases, it is still irreplaceable. This is strongly evidenced by the number of active clinical trials evaluating vincristine in combination cancer therapy. Therefore, in this article, we have reviewed the most common cancer treatment regimens employing vincristine and bring an overview of current trends in the clinical development of this compound.<\/jats:p>","DOI":"10.3390\/biology10090849","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T08:42:32Z","timestamp":1630399352000},"page":"849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5633-2202","authenticated-orcid":false,"given":"Jan","family":"\u0160kubn\u00edk","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1055-4026","authenticated-orcid":false,"given":"Vladim\u00edra Svobodov\u00e1","family":"Pavl\u00ed\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5698-4366","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Ruml","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3008-1396","authenticated-orcid":false,"given":"Silvie","family":"Rimpelov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/ja00867a049","article-title":"Vinca alkaloids. XI.1Structures of leurocristine (LCR) and vincaleukoblastine (VLB)2","volume":"84","author":"Neuss","year":"1962","journal-title":"J. Am. Chem. Soc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1200\/JCO.2014.57.1034","article-title":"The leukemias: A half-century of discovery","volume":"32","author":"Freireich","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"\u0160kubn\u00edk, J., Jur\u00e1\u0161ek, M., Ruml, T., and Rimpelov\u00e1, S. (2020). Mitotic poisons in research and medicine. Molecules, 25.","DOI":"10.3390\/molecules25204632"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13684","DOI":"10.1073\/pnas.1414572111","article-title":"A previously undescribed tubulin binder","volume":"111","author":"Field","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0163-7258(91)90081-V","article-title":"Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules","volume":"51","author":"Himes","year":"1991","journal-title":"Pharmacol. Ther."},{"key":"ref_7","first-page":"2212","article-title":"Mechanism of inhibition of cell proliferation by vinca alkaloids","volume":"51","author":"Jordan","year":"1991","journal-title":"Cancer Res."},{"key":"ref_8","first-page":"106","article-title":"Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management","volume":"25","author":"Boussios","year":"2012","journal-title":"Ann. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1523-1747.2003.12175.x","article-title":"Molecular mechanisms of chemotherapy-induced hair loss","volume":"8","author":"Botchkarev","year":"2003","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0749-2081(92)90027-Z","article-title":"Chemotherapy-induced myelosuppression","volume":"8","author":"Maxwell","year":"1992","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0022-3476(76)80416-7","article-title":"Overdosage with vincristine","volume":"89","author":"Kaufman","year":"1976","journal-title":"J. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0014-2964(79)90295-0","article-title":"Augmentation of vincristine-induced thrombocytosis by norethisterone","volume":"15","author":"Cantwell","year":"1965","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mpo.2950130615","article-title":"Extravasation of dactinomycin, vincristine, and cisplatin: Studies in an animal model","volume":"13","author":"Buchanan","year":"1985","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1040-8428(98)00023-7","article-title":"Vincristine revisited","volume":"29","author":"Gidding","year":"1999","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1038\/s41598-020-66815-y","article-title":"A metabolomics approach for early prediction of vincristine-induced peripheral neuropathy","volume":"10","author":"Verma","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1096\/fj.15-272567","article-title":"Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy","volume":"29","author":"Kramer","year":"2015","journal-title":"FASEB J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21082","DOI":"10.1074\/jbc.M114.569574","article-title":"The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1","volume":"289","author":"Janes","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e20201452","DOI":"10.1084\/jem.20201452","article-title":"Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1\u03b2 release","volume":"218","author":"Starobova","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E295","DOI":"10.1016\/S2352-3026(20)30031-4","article-title":"Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): A systematic review and meta-analysis","volume":"7","author":"Linschoten","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: Golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: The good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-17-0898","article-title":"FDA approval summary: Trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen","volume":"23","author":"Barone","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1515\/jtim-2016-0011","article-title":"A little help from steroids in oncology","volume":"4","author":"Lossignol","year":"2016","journal-title":"J. Transl. Int. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JBM.S190784","article-title":"How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas","volume":"10","author":"Mohammed","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hon.2613","article-title":"Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP","volume":"37","author":"Mondello","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1568011054222364","article-title":"Etoposide, topoisomerase II and cancer","volume":"5","author":"Baldwin","year":"2005","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: A prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.15051","article-title":"R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: A multi-centre analysis","volume":"180","author":"Shah","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_33","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=etoposide+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_34","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=lenalidomide+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_35","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=ibrutinib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_36","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=chidamide+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_37","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=nelarabine+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_38","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=azacitidine+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_39","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=decitabine+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_40","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=venetoclax+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_41","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=dasatinib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_42","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=ponatinib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_43","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=romidepsin+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_44","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=vorinostat+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_45","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=bortezomib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_46","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=ixazomib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_47","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=acalabrutinib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_48","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=zanubrutinib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_49","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=umbralisib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_50","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=parsaclisib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_51","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=pralatrexate+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_52","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=duvelisib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_53","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=copanlisib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_54","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03147885."},{"key":"ref_55","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=iberdomide+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_56","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=TAK-659+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_57","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=carfilzomib+vincristine+cyclophosphamide+hydroxydaunorubicin+prednisone&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2018-99-117572","article-title":"Ixazomib in previously untreated indolent B-cell non-hodgkin lymphoma","volume":"132","author":"Graf","year":"2018","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: Final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_61","unstructured":"(2021, June 23). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=cancer&term=vincristine&cntry=&state=&city=&dist=&Search=Search&recrs=b."},{"key":"ref_62","unstructured":"(2021, June 23). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=cancer&term=vincristine&cntry=&state=&city=&dist=&Search=Search&recrs=a."},{"key":"ref_63","unstructured":"(2021, June 23). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=cancer&term=vincristine&cntry=&state=&city=&dist=&Search=Search&recrs=f."},{"key":"ref_64","unstructured":"(2021, June 23). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=cancer&term=vincristine&cntry=&state=&city=&dist=&Search=Search&recrs=d."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/stem.170314","article-title":"The molecular perspective: Methotrexate","volume":"17","author":"Goodsell","year":"1999","journal-title":"Stem Cells"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/1097-0142(196903)23:3<589::AID-CNCR2820230310>3.0.CO;2-A","article-title":"Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors","volume":"23","author":"Costanzi","year":"1969","journal-title":"Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/1097-0142(197701)39:1<21::AID-CNCR2820390105>3.0.CO;2-I","article-title":"Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors","volume":"39","author":"Bearden","year":"1977","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1016\/S0021-9258(19)43672-7","article-title":"Characteristics of vincristine-induced augmentation of methotrexate uptake in ehrlich ascites tumor-cells","volume":"248","author":"Fyfe","year":"1973","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00254981","article-title":"Vincristine-methotrexate combination chemotherapy and the influence of weight loss on experimental tumour growth","volume":"3","author":"Mulder","year":"1979","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_70","first-page":"1889","article-title":"Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia","volume":"63","author":"Chello","year":"1979","journal-title":"Cancer Treat Rep."},{"key":"ref_71","first-page":"351","article-title":"Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture","volume":"48","author":"Kano","year":"1988","journal-title":"Cancer Res."},{"key":"ref_72","first-page":"vdaa077","article-title":"High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma","volume":"2","author":"Freeman","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): A multicentre, single-arm, phase 2 trial","volume":"21","author":"Shimada","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2012.43.1817","article-title":"EMA\/CO for high-risk gestational trophoblastic neoplasia: Good outcomes with induction low-dose etoposide-cisplatin and genetic analysis","volume":"31","author":"Alifrangis","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.1997.15.7.2636","article-title":"EMA\/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients","volume":"15","author":"Bower","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1471-0528.1991.tb10369.x","article-title":"Results with the EMA\/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989","volume":"98","author":"Newlands","year":"1991","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/ijc.33403","article-title":"M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin\/cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia","volume":"148","author":"Singh","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","article-title":"Recent advances of cocktail chemotherapy by combination drug delivery systems","volume":"98","author":"Hu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Avenda\u00f1o, C., and Men\u00e9ndez, J.C. (2015). DNA alkylating agents. Medicinal Chemistry of Anticancer Drugs, Elsevier. [2nd ed.].","DOI":"10.1016\/B978-0-444-62649-3.00005-3"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1310\/hpj5202-98","article-title":"Procarbazine, lomustine, and vincristine (PCV) regimen for central nervous system tumors","volume":"52","author":"Solimando","year":"2017","journal-title":"Hosp. Pharm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cns.15.36","article-title":"Procarbazine, lomustine and vincristine or temozolomide: Which is the better regimen?","volume":"4","author":"Lassman","year":"2015","journal-title":"CNS Oncol."},{"key":"ref_82","first-page":"CD011773","article-title":"Procarbazine, lomustine and vincristine for recurrent highgrade glioma","volume":"7","author":"Parasramka","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1002\/onco.13701","article-title":"Radiotherapy plus procarbazine, lomustine, and vincristine versus radiotherapy plus temozolomide for IDH-mutant anaplastic astrocytoma: A retrospective multicenter analysis of the French POLA cohort","volume":"26","author":"Esteyrie","year":"2021","journal-title":"Oncologist"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.19.02983","article-title":"Comprehensive genomic analysis in NRG oncology\/RTOG 9802: A phase III trial of radiation versus dadiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma","volume":"38","author":"Bell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","article-title":"Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH","volume":"32","author":"Cairncross","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_86","first-page":"47","article-title":"Second malignancies complicating Hodgkin\u2019s disease in remission","volume":"1","author":"Canellos","year":"1975","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/3.suppl_4.S117","article-title":"Second cancer after the treatment for Hodgkin\u2019s disease: A report from the International Database on Hodgkin\u2019s Disease","volume":"3","year":"1992","journal-title":"Ann Oncol."},{"key":"ref_88","unstructured":"Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., Bast, R.C., Gansler, T.S., Holland, J.F., and Frei, E. (2021, May 27). Holland-Frei Cancer Medicine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK13999\/."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann. Intern. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cen.12590","article-title":"Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: Own experience and overview of the contemporary literature","volume":"82","author":"Deutschbein","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: Systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","article-title":"Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas","volume":"8","author":"Asai","year":"2017","journal-title":"Horm Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0031-1279704","article-title":"Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: A single-center experience","volume":"119","author":"Deutschbein","year":"2011","journal-title":"Exp. Clin. Endocrinol. Diabet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/cam4.3298","article-title":"Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials","volume":"9","author":"Andre","year":"2020","journal-title":"Cancer Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00277-021-04460-9","article-title":"Advanced Hodgkin lymphoma in the East of England: A 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial","volume":"100","author":"Russell","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: Final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Raymakers, A.J.N., Costa, S., Cameron, D., and Regier, D.A. (2020). Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin\u2019s lymphoma: A probabilistic analysis. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07374-3"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12094-020-02483-8","article-title":"ABVD and BEACOPP regimens\u2019 effects on fertility in young males with Hodgkin lymphoma","volume":"23","author":"Amin","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s10815-020-01844-0","article-title":"Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma","volume":"37","author":"Policiano","year":"2020","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/em.22216","article-title":"Genomic chaos in peripheral blood lymphocytes of Hodgkin\u2019s lymphoma patients one year after ABVD chemotherapy\/radiotherapy","volume":"59","author":"Ramos","year":"2018","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u2264 16 years) low grade glioma\u2014A final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/neuonc\/nov057","article-title":"A pilot study using carboplatin, vincristine, and temozolomide in children with progressive\/symptomatic low-grade glioma: A Children\u2019s Oncology Group study","volume":"17","author":"Chintagumpala","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1002\/cncr.27563","article-title":"Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity","volume":"118","author":"Qaddoumi","year":"2012","journal-title":"Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e28882","DOI":"10.1002\/pbc.28882","article-title":"Chemoreduction with topotecan and vincristine: Quantifying tumor response in bilateral retinoblastoma patients","volume":"68","author":"King","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4143\/crt.2016.511","article-title":"Topotecan-vincristine-doxorubicin in stage 4 high-risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN study","volume":"50","author":"Amoroso","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/pbc.25837","article-title":"Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma: A report from the Children\u2019s Oncology Group","volume":"63","author":"Mascarenhas","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/CAD.0000000000001021","article-title":"Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab","volume":"32","author":"Papageorgiou","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Venkatramani, R., Malogolowkin, M., Davidson, T.B., May, W., Sposto, R., and Mascarenhas, L. (2013). A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (Vitb) in pediatric patients with relapsed solid tumors. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068416"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/pbc.24785","article-title":"Treatment of multiply relapsed Wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab","volume":"61","author":"Venkatramani","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/pbc.24547","article-title":"Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors","volume":"60","author":"Wagner","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MPH.0000000000000934","article-title":"Vincristine, irinotecan, and bevacizumab in relapsed Wilms tumor with diffuse anaplasia","volume":"40","author":"Schiavetti","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: An Eastern Cooperative Oncology Group study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_116","unstructured":"(2021, May 27). NCT04692155, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04692155."},{"key":"ref_117","unstructured":"(2021, May 27). NCT03677141, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03677141."},{"key":"ref_118","unstructured":"(2021, May 27). NCT03467373, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03467373."},{"key":"ref_119","unstructured":"(2021, May 27). NCT01527149, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01527149."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: An open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_121","unstructured":"(2021, May 27). NCT01445535, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01445535."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/10428194.2017.1387908","article-title":"Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas","volume":"59","author":"Roswarski","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: A phase 2 clinical trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: A single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_125","unstructured":"(2021, May 27). NCT04824092, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04824092."},{"key":"ref_126","unstructured":"(2021, May 27). NCT04661007, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04661007."},{"key":"ref_127","unstructured":"(2021, May 27). NCT04134936, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04134936."},{"key":"ref_128","unstructured":"(2021, May 27). NCT03518112, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03518112."},{"key":"ref_129","unstructured":"(2021, May 27). NCT04448834, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04448834."},{"key":"ref_130","unstructured":"(2021, May 27). NCT03914625, Available online: https:\/\/clinicaltrials.gov\/show\/NCT03914625."},{"key":"ref_131","unstructured":"(2021, May 27). NCT03147612, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03147612."},{"key":"ref_132","unstructured":"(2021, May 27). NCT02877303, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02877303."},{"key":"ref_133","unstructured":"(2021, May 27). NCT03643276, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03643276."},{"key":"ref_134","unstructured":"(2021, May 27). NCT02003222, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02003222."},{"key":"ref_135","unstructured":"(2021, May 27). NCT02734771, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02734771."},{"key":"ref_136","unstructured":"(2021, May 27). NCT02398240, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02398240."},{"key":"ref_137","unstructured":"(2021, May 27). NCT02166463, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02166463."},{"key":"ref_138","unstructured":"(2021, May 27). NCT01920932, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01920932."},{"key":"ref_139","unstructured":"(2021, May 27). NCT04139304, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04139304."},{"key":"ref_140","unstructured":"(2021, May 27). NCT03384654, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03384654."},{"key":"ref_141","unstructured":"(2021, May 27). NCT03860844, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03860844."},{"key":"ref_142","unstructured":"(2021, May 27). NCT01030900, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01030900."},{"key":"ref_143","unstructured":"(2021, May 27). NCT00069238, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00069238."},{"key":"ref_144","unstructured":"(2021, May 27). NCT01256398, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01256398."},{"key":"ref_145","unstructured":"(2021, May 27). NCT04231877, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04231877."},{"key":"ref_146","unstructured":"(2021, May 27). NCT03274492, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03274492."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/CCO.0000000000000212","article-title":"Targeting the programmed death-1\/programmed death-ligand 1 axis in lymphoma","volume":"27","author":"Cheah","year":"2015","journal-title":"Curr. Opin. Oncol."},{"key":"ref_148","unstructured":"(2021, May 27). NCT04796012, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04796012."},{"key":"ref_149","unstructured":"(2021, May 27). NCT04759586, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04759586."},{"key":"ref_150","unstructured":"(2021, May 27). NCT03586999, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03586999."},{"key":"ref_151","unstructured":"(2021, May 27). NCT03749018, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03749018."},{"key":"ref_152","unstructured":"(2021, May 27). NCT03704714, Available online: https:\/\/clinicaltrials.gov\/show\/NCT03704714."},{"key":"ref_153","unstructured":"(2021, May 27). NCT04058470, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04058470."},{"key":"ref_154","unstructured":"(2021, May 27). NCT03407144, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03407144."},{"key":"ref_155","unstructured":"(2021, May 27). NCT04113226, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04113226."},{"key":"ref_156","unstructured":"(2021, May 27). NCT03003520, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03003520."},{"key":"ref_157","unstructured":"(2021, May 27). NCT04181489, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04181489."},{"key":"ref_158","unstructured":"(2021, May 27). NCT04023916, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04023916."},{"key":"ref_159","unstructured":"(2021, May 27). NCT03244176, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03244176."},{"key":"ref_160","unstructured":"(2021, May 27). NCT03786783, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03786783."},{"key":"ref_161","unstructured":"(2021, May 27). NCT02306161, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02306161."},{"key":"ref_162","unstructured":"(2021, May 27). NCT03991884, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03991884."},{"key":"ref_163","unstructured":"(2021, May 27). NCT03851081, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03851081."},{"key":"ref_164","unstructured":"(2021, May 27). NCT02981628, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02981628."},{"key":"ref_165","unstructured":"(2021, May 27). NCT03249870, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03249870."},{"key":"ref_166","unstructured":"(2021, May 27). NCT01925131, Available online: https:\/\/clinicaltrials.gov\/show\/NCT01925131."},{"key":"ref_167","unstructured":"(2021, May 27). NCT04747912, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04747912."},{"key":"ref_168","unstructured":"(2021, May 27). NCT04307576, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04307576."},{"key":"ref_169","unstructured":"(2021, May 27). NCT03150693, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03150693."},{"key":"ref_170","unstructured":"(2021, May 27). NCT01371630, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01371630."},{"key":"ref_171","unstructured":"(2021, May 27). NCT03817853, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03817853."},{"key":"ref_172","unstructured":"(2021, May 27). NCT03269669, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03269669."},{"key":"ref_173","unstructured":"(2021, May 27). NCT02529852, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02529852."},{"key":"ref_174","unstructured":"(2021, May 27). NCT01332968, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01332968."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/cbdd.13758","article-title":"Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors","volume":"97","author":"Syed","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bmcl.2018.11.023","article-title":"Seco-4-methyl-DCK derivatives as potent chemosensitizers","volume":"29","author":"Guo","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"112555","DOI":"10.1016\/j.ejmech.2020.112555","article-title":"New Seco-DSP derivatives as potent chemosensitizers","volume":"204","author":"Wan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"113336","DOI":"10.1016\/j.ejmech.2021.113336","article-title":"Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7\/ADR cell","volume":"216","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"153528","DOI":"10.1016\/j.phymed.2021.153528","article-title":"A novel flavonoid from Fissistigma cupreonitens, 5-hydroxy-7,8-dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance","volume":"85","author":"Teng","year":"2021","journal-title":"Phytomedicine"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/cts.13012","article-title":"Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine","volume":"14","author":"Diouf","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Buzun, K., Gornowicz, A., Lesyk, R., Bielawski, K., and Bielawska, A. (2021). Autophagy Modulators in Cancer Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115804"},{"key":"ref_182","first-page":"1020","article-title":"LncRNA MEG3 promotes the sensitivity of vincristine by inhibiting autophagy in lung cancer chemotherapy","volume":"22","author":"Xia","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_183","first-page":"3526","article-title":"Silencing of lncRNA XIST suppresses proliferation and autophagy and enhances vincristine sensitivity in retinoblastoma cells by sponging miR-204-5p","volume":"24","author":"Yao","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1568009617666170330105433","article-title":"Autophagy inhibition in childhood nephroblastoma and the therapeutic significance","volume":"18","author":"Li","year":"2018","journal-title":"Curr. Cancer Drug Targets."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/cmdc.202000004","article-title":"Discovery of novel autophagy inhibitors and their sensitization abilities for vincristine-resistant esophageal cancer cell line Eca109\/VCR","volume":"15","author":"Shan","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_186","unstructured":"(2021, August 18). American Childhood Cancer Organization. Available online: https:\/\/www.acco.org\/blog\/the-vincristine-drug-shortage-update\/."},{"key":"ref_187","unstructured":"(2021, August 18). Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/dsp_ActiveIngredientDetails.cfm?AI=Vincristine%20Sulfate%20Injection,%20USP%20(Preservative-Free)&st=c."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/9\/849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:01Z","timestamp":1760165581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/9\/849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":187,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["biology10090849"],"URL":"https:\/\/doi.org\/10.3390\/biology10090849","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]}}}